Download PDF
Semin Thromb Hemost 2003; 29(3): 301-308
DOI: 10.1055/s-2003-40968
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Role of Coagulation and Fibrinolytic System in Prostate Cancer

Manish Kohli1 , Varsha Kaushal2 , Paulette Mehta2
  • 1Staff Physician, Division of Hematology/Oncology, Department of Medicine, Central Arkansas Veterans Healthcare System, and Assistant Professor of Medicine, Division of Hematology/Oncology, University of Arkansas for Medical Sciences
  • 2Central Arkansas Veterans Healthcare System and Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Further Information

Publication History

Publication Date:
30 July 2003 (online)

    Permissions and Reprints

ABSTRACT

Patients with prostate carcinoma paradoxically have both a hypercoagulable state and a bleeding diathesis. Hypercoagulability manifested by venous and arterial thrombosis has been documented in several large clinical trials. However, many investigators have reported a high risk of postoperative bleeding in prostate cancer patients. Disseminated intravascular coagulopathy has also been commonly noted at different clinical stages of this indolent cancer. In this article we review clinical, laboratory, and experimental evidence for abnormalities of various components of the coagulation and plasminogen pathways and analyze their contribution in prostate cancer growth, progression, and angiogenesis. Finally, we propose potential therapeutic antiangiogenic strategies in patients with prostate cancer.

KEYWORDS

Prostate cancer - hypercoagulability - bleeding - fibrinolysis - angiogenesis

REFERENCES

  • 1 The Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate.  Surg Gynecol Obstet . 1967;  124 1011-1101
    PubMedGoogle Scholar
  • 2 De Voogt J H, Smith P H, Pavone-Macaluso M. et al . Cardiovascular side effects of diethylstilbesterol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.  J Urol . 1986;  135 303-307
    PubMedGoogle Scholar
  • 3 Adamson A S, Witheerow R O, Francis J L, Snell M E. Coagulopathy in the prostate cancer patient: prevalence and clinical relevance.  Ann R Coll Surg Engl . 1993;  75 100-104
    PubMedGoogle Scholar
  • 4 Sack G H, Levin J, Bell W R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features.  Medicine (Baltimore) . 1977;  56 1-37
    PubMedGoogle Scholar
  • 5 Blombäck M, Hedlund P O, Sawe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications?.  Thromb Res . 1988;  49(Suppl) 111-121
    CrossrefPubMedGoogle Scholar
  • 6 Carlsson L A, Bottiger L E. Risk factors of ischemic heart disease in men and women. Results of the 19 year old follow up of the Stockholm prospective study.  Acta Med Scand . 1985;  218 207-211
    PubMedGoogle Scholar
  • 7 Aro J, Haapiaainen R, Sane T. et al . Effects of orchiectomy and polyestradiol phosphate on serum lipoprotein lipids and glucose tolerance in prostatic cancer patients.  Eur Urol . 1990;  17 229-235
    PubMedGoogle Scholar
  • 8 von Schoultz B, Carlstrom J, Collste L. et al . Estrogen therapy and liver function-metabolic effects of oral and parenteral administration.  Prostate . 1989;  14 389-395
    PubMedGoogle Scholar
  • 9 Elkik F, Gompel A, Mercier B C. et al . Effects of percutaneous estradiol and conjugated estrogens on the level of plasma proteins and triglycerides in post-menopausal women.  Am J Obstet Gynecol . 1982;  143 888-892
    PubMedGoogle Scholar
  • 10 Geenen R WF, Delaere K PJ, Van Wersch W J J. Hematological variables in prostate carcinoma patients.  Acta Urol Belg . 1996;  64 21-26
    PubMedGoogle Scholar
  • 11 Kohli M, Fink L, Spencer H J, Zent C S. Advanced prostate cancer activates coagulation: a controlled study comparing activation markers of coagulation in ambulatory patients with advanced prostate cancer to age and healthy male controls.  Blood Coagul Fibrinolysis . 2002;  13 1-5
    CrossrefPubMedGoogle Scholar
  • 12 Wojtukiewicz M Z, Zacharski L R, Memoli V A. et al . Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.  Cancer . 1991;  67 1377-1383
    PubMedGoogle Scholar
  • 13 Abdlkadir S A, Carvalhal G F, Kaleem Z. et al . Tissue factor expression and angiogenesis in human prostate carcinoma.  Hum Pathol . 2000;  31 443-447
    CrossrefPubMedGoogle Scholar
  • 14 Lwaleed B A, Francis J L, Chisholm M. Urinary tissue factor levels in patients with bladder and prostate cancer.  Eur J Surg Oncol . 2000;  26 44-49
    CrossrefPubMedGoogle Scholar
  • 15 Adamson A S, Francis J L, Witherow R, Snell M E. Urinary tissue factor levels in transitional cell carcinoma of the bladder.  J Urol . 1992;  148(2 Pt 1) 449-452
    PubMedGoogle Scholar
  • 16 Bromberg M E, Capello M. Cancer and blood coagulation: molecular aspects.  Cancer J Sci Am . 1999;  5 132-138
    PubMedGoogle Scholar
  • 17 Stone M J, Ruf W, Miles D J, Edington T S, Wright P E. Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization.  Biochem J . 1995;  310(Pt 2) 605-614
    PubMedGoogle Scholar
  • 18 Rao L MV, Rapaport S I. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation.  Blood . 1987;  69 645-651
    PubMedGoogle Scholar
  • 19 Kataoka H, Uchino H, Asada Y. et al . Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver.  Int J Cancer . 1997;  72 878-884
    CrossrefPubMedGoogle Scholar
  • 20 Werling R W, Zacharski L R, Kisiel W. et al . Distribution of tissue factor pathway inhibitor in normal and malignant human tissues.  Thromb Haemost . 1993;  69 366-369
    Google Scholar
  • 21 Petersen L C, Sprecher C A, Foster D C. et al . Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.  Biochemistry . 1996;  35 266-272
    Google Scholar
  • 22 Konduri S D, Tasiou A, Chandrasekhar N, Rao J S. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro.  Int J Oncol . 2001;  18 127-131
    Google Scholar
  • 23 Carrel A, Burrows M T. Cultivation in vitro of malignant tumors.  J Exp Med . 1911;  13 571-575
    CrossrefPubMedGoogle Scholar
  • 24 Cliffton E E, Grossi C E. Fibrinolytic activity of human tumors as measured by the fibrin plate method.  Cancer . 1955;  8 1146-1154
    PubMedGoogle Scholar
  • 25 Goldhaber P, Corman I, Ormsbee R A. Experimental alteration of the ability of tumor cells to lyse plasma clots in vitro.  Proc Soc Exp Biol Med . 1947;  66 590-595
    PubMedGoogle Scholar
  • 26 Tagnon H J, Whitmore W F, Schulman P, Kravitc H C. The significance of fibrinolysis occurring in patients with metastatic prostate cancer.  Cancer . 1953;  6 63-67
    PubMedGoogle Scholar
  • 27 Thurston A V, Briant S L. Aspirin and post-prostatectomy hemorrhage.  Br J Urol . 1993;  71 574-576
    CrossrefPubMedGoogle Scholar
  • 28 Carroll V A, Binder B R. The role of the plasminogen activation system in cancer.  Semin Thromb Hemost . 1999;  25 183-197
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Plow E F, Felez J, Miles L A. Cellular regulation of fibrinolysis.  Thromb Haemost . 1991;  66 32-36
    PubMedGoogle Scholar
  • 30 Åstedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture.  Nature . 1976;  261 595-597
    PubMedGoogle Scholar
  • 31 Kirchheimer J C, Pflueger H, Ritschl P, Hienert G, Binder B R. Plasminogen activator activity in bone metastases of prostatic carcinomas as compared to primary tumors.  Invasion Metastasis . 1985;  5 344-355
    PubMedGoogle Scholar
  • 32 Kirchheimer J C, Binder B R, Pflueger H, Hienert G. Does plasma urokinase antigen reflect tumor urokinase in prostatic carcinoma?.  Thromb Haemost . 1985;  54 729
    PubMedGoogle Scholar
  • 33 Duffy M J, O'Grady P, Devaney D. et al . Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report.  Cancer . 1988;  62 531-533
    PubMedGoogle Scholar
  • 34 Sappino A P, Busso N, Belin D, Vassali J D. Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas.  Cancer Res . 1987;  47 4043-4046
    PubMedGoogle Scholar
  • 35 Corasanti J G, Celik C, Camiolo S M. et al . Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification.  J Natl Cancer Inst . 1980;  65 345-351
    PubMedGoogle Scholar
  • 36 De Bruin A P, Griffioen G, Verspaget H W, Verheijen J H, Lamers C B. Plasminogen activators and tumor development in the human colon: activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas.  Cancer Res . 1987;  47 4654-4657
    PubMedGoogle Scholar
  • 37 Nekarda H, Schmitt M, Ulm K. et al . Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.  Cancer Res . 1994;  54 2900-2907
    PubMedGoogle Scholar
  • 38 Hasui Y, Suzumiya J, Marutsuka K. et al . Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.  Cancer Res . 1989;  49 1067-1070
    PubMedGoogle Scholar
  • 39 Hofmann R, Lehmer A, Hartung R. et al . Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer.  J Urol . 1996;  155 858-862
    PubMedGoogle Scholar
  • 40 Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.  Cancer . 1996;  78 487-492
    CrossrefPubMedGoogle Scholar
  • 41 Camiolo S M, Markus G, Piver M S. Plasminogen activator content of gynecological tumors and their metastases.  Gynecol Oncol . 1987;  26 364-373
    CrossrefPubMedGoogle Scholar
  • 42 Soszka T, Olszewski K. Plasminogen activators and their inhibitors in normal, hyperplastic and carcinomatous human endometrium.  Thromb Res . 1986;  42(Suppl) 835-846
    CrossrefPubMedGoogle Scholar
  • 43 Wilson E L, Jacobs P, Francis G E. et al . Secretion of plasminogen activators by normal bone marrow cells and leukemic myeloid cells.  Fibrinolysis . 1992;  6 77-79
    CrossrefPubMedGoogle Scholar
  • 44 Duffy M J, O'Grady P, Devaney D. et al . Tissue-type plasminogen activator, a new prognostic marker in breast cancer.  Cancer Res . 1988;  48 1348-1349
    PubMedGoogle Scholar
  • 45 Gaylis F D, Keer H N, Wilson M J. et al . Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.  J Urol . 1989;  142 193-198
    PubMedGoogle Scholar
  • 46 Keer H N, Gaylis F D, Kozlowski J M. et al . Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.  Prostate . 1991;  18 201-214
    PubMedGoogle Scholar
  • 47 Achbarou A, Kaiser S, Tremblay G. et al . Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo.  Cancer Res . 1994;  54 2372-2377
    PubMedGoogle Scholar
  • 48 Rabbani S A, Harakidas P, Davidson D J, Henkin J, Mazar A P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA).  Int J Cancer . 1995;  63 840-845
    PubMedGoogle Scholar
  • 49 Goltzman D, Bolivar I, Moroz L A, Rabbani S A. Studies on the pathogenesis of osteoblastic metastases by prostate cancer.  Adv Exp Med Biol . 1992;  324 165-171
    PubMedGoogle Scholar
  • 50 Hollas W, Hoosein N, Chung L WK. et al . Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines.  Thromb Haemost . 1992;  68 662-666
    PubMedGoogle Scholar
  • 51 Pedersen H, Schmitt M, Ronne E. et al . A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.  J Clin Invest . 1993;  92 2160-2167
    PubMedGoogle Scholar
  • 52 Miyake H, Hara I, Yamanaka K. et al . Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.  Prostate . 1999;  39 123-129
    CrossrefPubMedGoogle Scholar
  • 53 Hienert G, Kirchheimer J C, Pflueger H, Binder B R. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas.  J Urol . 1988;  140 1466-1469
    PubMedGoogle Scholar
  • 54 Levin E G, Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells.  J Cell Biol . 1987;  105(6 Pt 1) 2543-2549
    CrossrefPubMedGoogle Scholar
  • 55 Laiho M, Saksela O, Andreasen P A, Keski O J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta.  J Cell Biol . 1986;  103(6 Pt 1) 2403-2410
    CrossrefPubMedGoogle Scholar
  • 56 Cubellis M V, Wun T C, Blsi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1.  EMBO J . 1990;  9 1079-1085
    PubMedGoogle Scholar
  • 57 Del Rosso M, Fibbi G, Dini G. et al . Modulation of surface associated urokinase in different cell lines: evidence for urokinase interiorization and degradation.  Semin Thromb Hemost . 1991;  17 262-267
    PubMedGoogle Scholar
  • 58 Soff G A, Sanderowitz J, Gately S. et al . Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.  J Clin Invest . 1995;  96 2593-2600
    CrossrefPubMedGoogle Scholar
  • 59 Swiercz R, Keck R W, Skrzypczak J E, Selman S H, Jankun J. Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice.  Oncol Rep . 2001;  8 463-470
    PubMedGoogle Scholar
  • 60 Kwaan H C, Wang J, Svoboda K, Declerck P J. Plasminogen activator inhibitor 1 may promote tumor growth through inhibition of apoptosis.  Br J Cancer . 2000;  82 1702-1708
    CrossrefPubMedGoogle Scholar
  • 61 Foekens J A, Portengen H, Look M P. et al . Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.  J Clin Oncol . 1994;  12 1648-1658
    PubMedGoogle Scholar
  • 62 Janicke F, Pache L, Schmitt M. et al . Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.  Cancer Res . 1994;  54 2527-2530
    PubMedGoogle Scholar
  • 63 Geeenen R WF, Delaere K PJ, van Wersch W J. Hematological variables in prostatic carcinoma patients.  Acta Urol Belg . 1996;  64 21-26
    PubMedGoogle Scholar
  • 64 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases.  Review Nat Med . 1995;  1 27-31
    CrossrefPubMedGoogle Scholar
  • 65 Ferrer F A, Miller L J, Andrawis R I. et al . Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells.  J Urol . 1997;  157 2329-2333
    PubMedGoogle Scholar
  • 66 Huss W J, Hanrahan C F, Barrios R J. et al . Angiogenesis and prostate cancer: identification of a molecular progression switch.  Cancer Res . 2001;  61 2736-2743
    PubMedGoogle Scholar
  • 67 Jones A, Fujiyama C, Turner K. et al . Elevated serum vascular endothelial growth factor in patients with hormone-escaped prostate cancer.  BJU Int . 2000;  85 276-280
    CrossrefPubMedGoogle Scholar
  • 68 Duque J LF, Loughlin K R, Adam R M. et al . Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.  Urology . 1999;  54 523-537
    CrossrefPubMedGoogle Scholar
  • 69 Haggstrom S, Bergh A, Damber J. Vascular endothelial growth factor content in metastasizing and non metastasizing Dunning prostate carcinoma.  Prostate . 2000;  45 42-50
    PubMedGoogle Scholar
  • 70 Wynendaele W, Derua R, Hoylaerts M F. et al . Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?.  Ann Oncol . 1999;  10 965-971
    CrossrefPubMedGoogle Scholar
  • 71 Grand R JA, TurnellAS, Grabham P W. Cellular consequences of thrombin receptor activation.  Biochem J . 1996;  313 353-368
    PubMedGoogle Scholar
  • 72 Coughlin S R. Thrombin signaling and protease-activated receptors.  Nature . 2000;  407 258-264
    CrossrefPubMedGoogle Scholar
  • 73 Brass S. Platelets and proteases.  Nature . 2000;  413 26-27
    PubMedGoogle Scholar
  • 74 Griffin C T, Srinivasan Y, Zheng Y W, Huang W, Coughlin S R. A role of thrombin receptor signaling in endothelial cells during embryonic development.  Science . 2001;  293 1666-1670
    CrossrefPubMedGoogle Scholar
  • 75 Rudroff C, Striegler S, Schilli M, Scheele J. Thrombin enhances adhesion in pancreatic cancer in vitro through the activation of the thrombin receptor PAR 1.  Eur J Surg Oncol . 2001;  27 472-476
    CrossrefPubMedGoogle Scholar
  • 76 Klepfish A, Greco M A, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix.  Int J Cancer . 1993;  53 978-982
    PubMedGoogle Scholar
  • 77 Nierodzik M L, Bain R M, Liu L X. et al . Presence of seven transmembrane thrombin receptors on human tumor cells: effect of activation on tumor adhesion to platelets and tumor tyrosine phosphorylation.  Br J Hematol . 1996;  92 452-457
    CrossrefPubMedGoogle Scholar
  • 78 Nierodzik M L, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in-vitro and metastasis in vivo.  Cancer Res . 1992;  52 3267-3272
    PubMedGoogle Scholar
  • 79 Harlabopolous G C, Grant D S, Kleinman H K. et al . Thrombin promotes endothelial cell alignment in matrigel in vitro and angiogenesis in vivo.  Am J Physiol . 1997;  273 239-245
    PubMedGoogle Scholar
  • 80 Herbert J M, Dupuy E, Laplace M C. et al . Thrombin induces endothelial growth via both a proteolytic and a non proteolytic pathway.  Biochem J . 1994;  303 227-231
    PubMedGoogle Scholar
  • 81 Tsopanoglou N E, Maragoudakis M E. On the endothelial growth factor activity on endothelial cells by up-regulation of its receptors.  J Biol Chem . 1999;  274 23969-23976
    CrossrefPubMedGoogle Scholar
  • 82 Maragoudakis M E, Tsopanoglou N E, Andriopoulou P, Maragoudakis M M. Effects of thrombin/thrombosis in angiogenesis and tumour progression.  Matrix Biol . 2000;  19 345-351
    CrossrefPubMedGoogle Scholar
  • 83 Huang Y Q, Li J J, Hu L, Lee M, Karpatkin S. Thrombin induces increased expression and secretion of VEGF from human FS4 fibroblast, DU 145 prostate cells and CHRF megakaryocytes.  Thromb Hemost . 2001;  86 1094-1098
    PubMedGoogle Scholar
  • 84 Gately S, Twardowski P, Stack M S. et al . Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.  Cancer Res . 1996;  56 4887-4890
    PubMedGoogle Scholar
      >